Enliven Therapeutics, Inc.
ELVN
$18.27
-$1.42-7.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.67% | -11.49% | -19.31% | -54.43% | -102.83% |
| Total Depreciation and Amortization | 2.56% | 2.56% | 5.41% | 17.91% | 21.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 376.00% | 258.36% | 13.59% | 73.87% | 83.13% |
| Change in Net Operating Assets | -109.33% | 58.25% | -455.27% | 45.14% | 801.65% |
| Cash from Operations | -37.82% | 23.29% | -69.60% | -12.08% | -53.25% |
| Capital Expenditure | 100.00% | -37.50% | 97.73% | 35.48% | 86.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -98.12% | 141.79% | 77.77% | -- | -- |
| Cash from Investing | -98.12% | 141.71% | 77.78% | -57,593.55% | 38,402.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 44,313.33% | -99.31% | 1,180.85% | 10.14% | 592.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 44,313.33% | 362.82% | 164.04% | -61.98% | 103.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.64% | 107.23% | 68.57% | -77.36% | 347.52% |